Skip to content

Efinaconazole

Azole Antifungal — DERMATOLOGICALS

Also known as: jublia, KP-103

OfpFDA approvedPMDA approvedATC D01AC19

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Efinaconazole is an ofp drug in the Azole Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 2014. DrugCentral lists 1 molecular target, including Lanosterol 14-alpha demethylase. Recorded indications include Onychomycosis due to dermatophyte, Onychomycosis due to Trichophyton mentagrophytes and Onychomycosis of toenails.

  • Approval status: ofp (first approved 2014 by the FDA).
  • Drug class: Azole Antifungal.
  • Molecular targets: Lanosterol 14-alpha demethylase (1 listed in DrugCentral).
  • Indications: Onychomycosis due to dermatophyte, Onychomycosis due to Trichophyton mentagrophytes and Onychomycosis of toenails.
  • ATC code: D01AC19 (Imidazole and triazole derivatives).
  • Molecular formula: C18H22F2N4O; molecular weight 348.40 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

  • Onychomycosis due to dermatophyte
  • Onychomycosis due to Trichophyton mentagrophytes
  • Onychomycosis of toenails

Mechanism & targets

Established pharmacologic classAzole Antifungal

Molecular targets (1)

TargetGeneActionActivity
Lanosterol 14-alpha demethylase—inhibitor—

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2014-07-04PMDA——
2014-06-06FDA—DOW PHARM

ATC classification

ATC codeTherapeutic hierarchy
D01AC19DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Imidazole and triazole derivatives

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Bronchopulmonary aspergillosis allergic489.5
Blood calcium increased381.9
Aspiration338.4
Total lung capacity decreased334.3
Blood test abnormal318.7
Lung opacity317.0
Pleuritic pain266.0
Rales252.9
Sputum discoloured240.2
Transaminases increased230.3
Bronchiectasis218.0
Obstructive airways disorder197.9

Chemical structure

Molecular formulaC18H22F2N4O
Molecular weight348.40 g/mol
CAS number164650-44-6
InChIKeyNFEZZTICAUWDHU-RDTXWAMCSA-N
PubChem CID489181
C[C@@H](N1CCC(=C)CC1)[C@](O)(CN1C=NC=N1)C1=C(F)C=C(F)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Efinaconazole used for?

DrugCentral lists the following indications for Efinaconazole: Onychomycosis due to dermatophyte, Onychomycosis due to Trichophyton mentagrophytes and Onychomycosis of toenails.

How does Efinaconazole work?

Its molecular targets in DrugCentral include Lanosterol 14-alpha demethylase (inhibitor).

When was Efinaconazole first approved?

Efinaconazole was first approved by the FDA in 2014.

What drug class does Efinaconazole belong to?

Efinaconazole is in the Azole Antifungal class.

What is the chemical formula of Efinaconazole?

Efinaconazole has the molecular formula C18H22F2N4O and a molecular weight of 348.40 g/mol.

Browse: all drugs starting with E · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2014-06-06
AgencyFDA
Targets1
Indications3
FormulaC18H22F2N4O
DrugCentral ID4874
Interactive profile